Select a medication above to begin.
inosite
inositol
Entire Monograph
Reported Uses
- NOTE: see Herb & Supplement Effectiveness Rating Definitions table
- ARDS [Possibly Ineffective]
- anxiety [Possibly Ineffective]
- bipolar disorder [Insufficient Evidence]
- depression [Possibly Ineffective]
- diabetes [Insufficient Evidence]
- diabetic neuropathy [Possibly Ineffective]
- dyslipidemia [Insufficient Evidence]
- HTN [Insufficient Evidence]
- HTN, pregnancy-induced [Insufficient Evidence]
- hypothyroidism [Insufficient Evidence]
- infertility [Insufficient Evidence]
- insomnia [Insufficient Evidence]
- leukopenia, chemo-related [Insufficient Evidence]
- lithium-induced adverse effects [Insufficient Evidence]
- lung CA [Insufficient Evidence]
- metabolic syndrome [Possibly Effective]
- nonalcoholic fatty liver dz [Insufficient Evidence]
- obesity [Insufficient Evidence]
- obsessive-compulsive disorder [Insufficient Evidence]
- panic disorder [Insufficient Evidence]
- polycystic ovary syndrome [Possibly Effective]
- post-traumatic stress disorder [Insufficient Evidence]
- preterm labor prevention [Possibly Effective]
- psoriasis [Insufficient Evidence]
- retinopathy of prematurity [Possibly Ineffective]
- testosterone deficiency, age-related [Insufficient Evidence]
- trichotillomania [Insufficient Evidence]
Reported Doses
Safety/efficacy may not be established; reported doses may be derived from limited or potentially inadequate studies w/ variable regimens, multi-ingredient products, or where concentration of active ingredients may vary widely
Effectiveness Ratings
- [see Herb & Supplement Effectiveness Rating Definitions table]
bipolar disorder, peds pts
- [Insufficient Evidence]
- Dose: 80 mg/kg/dose PO qd; Max: 2 g/dose; Info: for pts 5-12 yo; used w/ or w/o eicosapentaenoic acid
diabetes mellitus, type 1
- [Insufficient Evidence]
- Dose: 1 g D-chiro-inositol PO qd; Info: used w/ folic acid and insulin
gestational diabetes prevention
- [Insufficient Evidence]
- Dose: 0.2-4 g myo-inositol PO qd; Alt: 2 g myo-inositol PO bid; Info: used w/ or w/o folic acid
HTN, pregnancy-induced
- [Insufficient Evidence]
- Dose: 2 g myo-inositol PO bid; Start: 1st trimester; Info: used w/ folic acid
hypothyroidism
- [Insufficient Evidence]
- Dose: 600 mg myo-inositol PO qd; Info: used w/ selenium
infertility
- [Insufficient Evidence]
- Dose: 4 g myo-inositol PO qd starting 1-3mo before ICSI, cont. until ovulation; Alt: 2 g myo-inositol PO bid starting day 3 of IVF cycle x2mo; 400 mg myo-inositol and 45 mg D-chiro-inositol PO tid; Info: used w/ or w/o folic acid
insomnia
- [Insufficient Evidence]
- Dose: 2 g myo-inositol PO qhs; Info: used w/ folic acid
leukopenia, chemo-induced
- [Insufficient Evidence]
- Dose: 390 mg PO bid; Info: used w/ inositol hexaphosphate 4% gel topically to surgical site; start 2wk before adjuvant chemo regimen, cont. until 2wk after last cycle
lithium-induced psoriasis
- [Insufficient Evidence]
- Dose: 6 g PO qd
metabolic syndrome
- [Possibly Effective]
- Dose: 2 g myo-inositol PO bid
nonalcoholic fatty liver dz
- [Insufficient Evidence]
- Dose: 4 g myo-inositol PO qd
obesity
- [Insufficient Evidence]
- Dose: 0.6-4.45 g PO qd
obsessive-compulsive disorder
- [Insufficient Evidence]
- Dose: 18 g PO qd
panic disorder
- [Insufficient Evidence]
- Dose: 12-18 g PO qd
polycystic ovary syndrome
- [Possibly Effective]
- Dose: 2 g PO bid; Alt: 4 g myo-inositol PO qd; 1-1.2 g D-chiro-inositol PO qd; 550 mg myo-inositol and 13.8 mg D-chiro-inositol PO bid; 550 mg myo-inositol and 150 mg D-chiro-inositol PO bid; Info: often used w/ folic acid
preterm labor prevention
- [Possibly Effective]
- Dose: 2 g myo-inositol PO bid; Alt: 1.1 g myo-inositol and 27.6 mg D-chiro-inositol PO qd; Info: for pts w/ gestational diabetes risk; used w/ folic acid
psoriasis
- [Insufficient Evidence]
- Dose: apply 40% cream topically qd-bid; Info: product containing amino-inositol and urea
testosterone deficiency, age-related
- [Insufficient Evidence]
- Dose: 600 mg D-chiro-inositol PO bid
Copyright © 2024. All Rights Reserved. Republication or redistribution, including by framing or similar means, is prohibited without the prior written consent of copyright holder.